New study results suggest Verdure Sciences’ Pomella pomegranate extract may improve cardiovascular-health markers in patients with myocardial infarction.
New study results1 out of India suggest Pomella, a pomegranate extract from Verdure Sciences (Noblesville, IN), may improve several cardiovascular-health markets in patients with myocardial infarction, including significant improvements to cholesterol levels.
For 30 days, 100 participants aged 20–60 with myocardial infarction were assigned to consume either a placebo or 300 mg/day of Pomella twice daily in addition to their regular prescribed medications. Compared to cardiac biomedical parameters assessed at baseline, researchers found that the Pomella group experienced significant improvements in mean levels of total cholesterol, LDL cholesterol, and HDL cholesterol at the end of the study period, with an observed increase in HDL cholesterol and a decrease in LDL cholesterol. Meanwhile, mean levels of triglycerides, serum homosystein, hs-CRP, and OX-LDL all showed significant improvements in the experimental group after participants added Pomella to their regular medication regimens for 30 days.
Verdure Sciences also noted that a separate study2, which was conducted by the same group of researchers, recently found that Pomella extract may significantly reduce blood glucose levels and HbA1C levels in patients with type 2 diabetes and myocardial infarction. That study asked 40 participants aged 20–55 to consume either 300 mg/day of Pomella or a placebo for 30 days, also in addition to their prescribed medication.
“We are very excited to see the additional support of Pomella’s efficacious capabilities and potential health applications,” said Sonya Cropper, vice president of marketing and innovation with Verdure Sciences, in an announcement of the study results. “It is impressive to see the impact Pomella has on biomarkers that influence health in these complementary clinical trials.”
Nutritional Outlook Magazine
1. Goyal R et al., “An antixoidative effect of Punica granatum (pomegranate) on biochemical parameters in patients with myocardial infarction: a double blind placebo controlled trial,” European Journal of Biomedical and Pharmaceutical Sciences, vol. 3, no. 5 (2016): 662–667
2. Goyal R et al., “Antixoidative effect of Puica granatum (pomegranate) on biochemical parameters in patients with diabetes mellitus (type 2) and myocardial infarction: a double blind placebo controlled trial,” International Journal of Advanced Research, vol. 4, no. 5 (2016): 857–864